Soft-tissue Sarcoma Clinical Trial
Official title:
Phase II Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas With Dysregulation of the mTOR Pathway
This is an open-label phase II study of TAK-228 for patients ≥ 18 years of age with complex genomic sarcomas exhibiting Phosphoinositide-3 Kinase (PI3K) pathway dysregulation. Patients must have surgically unresectable or metastatic disease that is refractory to at least one prior line of therapy (not including neoadjuvant or adjuvant therapy in a curative setting). Patients disease must also have evidence of progression prior to enrollment. The purpose of this study is to determine the antitumor activity in this group of patients. Patients must meet all eligibility criteria as detailed in section 10. A total of up to 33 patients will be included in the study. Patients will undergo screening evaluations to determine eligibility within 28 days of the first dose. All patients will be required to submit baseline tumor samples for analysis. Patients who have had their tumors tested commercially for PI3K/ AKT/mechanistic Target of Rapamycin (mTOR) alterations will be assessed on a case by case basis for eligibility and for determination as to whether additional tissue is required. TAK-228 will be administered orally at 3 mg daily for a 21 day cycle. Clinical and laboratory assessments will be made on day 1 of each cycle. Disease will be assessed by comparing unidimensional tumor measurements on pre and peritreatment imaging (CT or MRI) after weeks 6, 12, 18 and every 12 weeks thereafter. Response will be assessed according to RECIST 1.1. Therapy will continue until disease progression or unacceptable toxicity or withdrawal of consent.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
| Recruiting |
NCT02630368 -
A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)
|
Phase 1/Phase 2 | |
| Completed |
NCT01438554 -
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
|
Phase 1 | |
| Active, not recruiting |
NCT03602833 -
Phase I Study Compound 451238 and Radiotherapy in Soft-tissue Sarcoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03475953 -
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03242382 -
Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.
|
Phase 2 | |
| Recruiting |
NCT04181970 -
Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK
|
||
| Completed |
NCT01389050 -
High Precision RT For Soft-Tissue Sarcoma
|
Phase 2 | |
| Recruiting |
NCT03096912 -
A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma
|
Phase 2 | |
| Completed |
NCT02787642 -
A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma
|
Phase 1 | |
| Recruiting |
NCT03175718 -
INPWT on Wound Complications & Clinical Outcomes After Lower Extremity Sarcoma Surgery Preop Radiation Therapy Patients
|
N/A | |
| Recruiting |
NCT05741944 -
The Value of a Risk Prediction Tool (PERSARC) for Effective Treatment Decisions of Soft-tissue Sarcomas Patients
|
N/A | |
| Active, not recruiting |
NCT03016819 -
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
|
Phase 3 |